Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...
Eli Lilly (LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...